Clinical trials
Metastatic Adenocarcinoma clinical trials
Below are recruiting metastatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 245 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04205968RecruitingPhase 2
Testing ramucirumab with chemo for advanced small bowel cancer
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Anchorage, AlaskaAges 18 years+ - NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT07764497RecruitingPhase 2
Chemotherapy through liver artery for colorectal cancer that spread to liver
This trial tests giving chemotherapy directly into the liver artery for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to shrink the tumors and make the liver healthy enough for surgery.
Toronto, OntarioAges 18 years+ - NCT06702683Recruiting
Sintilimab blood levels in advanced stomach cancer
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Nanjing, JiangsuAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07462650RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced colorectal cancer
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
Shenzhen, GuangdongAges 18–75 - NCT07392346RecruitingPhase 2
Fruquintinib combo for advanced gastric cancer after immunotherapy
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06867497RecruitingPhase 1
Study of two forms of a pancreatic cancer drug
This trial compares two different versions of an investigational drug for metastatic pancreatic cancer to see how they work in the body and if they are safe. It may help find a better way to give the drug.
SeoulAges 19–74 - NCT06957678Enrolling by invitation
AI predicts lymph node spread in stomach cancer using scans and biopsy
This study uses artificial intelligence to predict whether stomach cancer has spread to nearby lymph nodes. By analyzing your CT/MRI scans and biopsy results before surgery, the AI may help doctors plan your treatment more precisely.
Shijiazhuang, None SelectedAges 18–80 - NCT06483555RecruitingPhase 1/Phase 2
Drug combo for basal-like pancreatic cancer
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT05346536Recruiting
Test blood test for a specific type of pancreatic cancer cell
This trial looks for pancreatic cancer markers in a blood sample (“liquid biopsy”), focusing on cells that show a certain protein (AXL). It may help doctors detect and better track advanced pancreatic cancer before or during first-line treatment.
MontpellierAges 18 years+ - NCT06952101Recruiting
Personalized treatment for rectal cancer to save the organ
This trial tests a personalized, step-by-step approach for rectal cancer that aims to avoid surgery and preserve the rectum. It is for patients whose tumor has shrunk significantly after chemoradiation, or who have early-stage high-risk cancer removed during a scope procedure.
Candiolo, TurinAges 18 years+ - NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07303465RecruitingPhase 2
Testing a new drug for KRAS G12D pancreatic cancer
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
NanjingAges 18–75 - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT07815834RecruitingPhase 3
FAPI-guided radiation with cadonilimab and chemo for colorectal cancer spread to the abdomen
This trial tests a new combination treatment for colorectal cancer that has spread only to the lining of the abdomen (peritoneum). It combines targeted radiation, an immunotherapy drug called cadonilimab, and standard chemotherapy to see if it can help control the disease better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75
Hear when a new Metastatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic adenocarcinoma?
- Yes. Clin2 currently lists 245 recruiting metastatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Prostate Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Gastric Cancer Adenocarcinoma Metastatic
- Metastatic Esophageal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.